Term ends Jun 6, 2028 · High confidence
20-year base term ended May 6, 2024
Held by Bioverativ Therapeutics Inc.
Filed May 6, 2004 as application 10/841,250 · Granted Jul 29, 2008
Base term plus 752 days of patent term adjustment (USPTO delay)
Today
2004
2028
Clock starts
May 6, 2004
May 6, 2004
Term ends
Jun 6, 2028
Jun 6, 2028
Granted
Jul 29, 2008
Jul 29, 2008
base term
patent term adjustment
fee events
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
752
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
12
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 752 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 6, 2004, when this application, 10/841,250, was filed | May 6, 2024 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +752 days, USPTO patent term adjustment record | May 28, 2026 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | +740 days, USPTO 35 U.S.C. 156 certificate | added to May 28, 2026: Jun 6, 2028 | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 6, 2028 | High confidence |
This family
| US 7,404,956 | this patent Jun 2028 | Jun 2028 |
| US 7,348,004 | In force Mar 2028 | Mar 2028 |
| Application PCT/US2006/000140 | PCT application no patent term | no patent term |
| US 7,862,820 | Term ended no later than Mar 2026 | no later than Mar 2026 |
| US 8,329,182 | Term ended no later than May 2024 | no later than May 2024 |
| US 8,932,830 | Term ended May 2024 | May 2024 |
| US 9,636,416 | Term ended May 2024 | May 2024 |
| US 11,401,322 | Term ended May 2024 | May 2024 |
8 of 12 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 1, 2004 Reel 16044, frame 307 | Peters, Robert T.; Mezo, Adam R.; Rivera, Daniel S.; Bitonti, Alan J.; Stattel, James; Low, Susan C. | Syntonix Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Jan 12, 2007 Reel 18764, frame 586 | Syntonix Pharmaceuticals, Inc. | Biogen Idec Inc. | Security Agreement |
| Mar 5, 2007 Reel 18964, frame 431 | Biogen Idec Inc. | Syntonix Pharmaceuticals, Inc. | Release & Reassignment |
| Apr 24, 2014 Reel 32753, frame 837 | Syntonix Pharmaceuticals, Inc. | Biogen Idec Hemophilia Inc. | Change of Name |
| Apr 30, 2015 Reel 35553, frame 325 | Biogen Idec Hemophilia Inc. | Biogen Hemophilia Inc. | Change of Name |
| Jul 2, 2015 Reel 36051, frame 773 | Biogen Hemophilia Inc. | Biogen Hemophilia Inc. | Change of Address |
| Feb 16, 2017 Reel 41735, frame 621 | Biogen Hemophilia Inc. | Bioverativ Therapeutics Inc. | Change of Name |
| Dec 15, 2021 Reel 58398, frame 627 | Peters, Robert T.; Mezo, Adam R.; Rivera, Daniel S.; Bitonti, Alan J.; Stattel, James; Low, Susan C. | Syntonix Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jun 2028
Term ends Jun 6, 2028. No further fees fall due before then
Note
The 752 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
238
later US patents cite this one
That is top 5% of utility patents granted in 2008 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.